News | CHUGAI PHARMACEUTICAL CO., LTD.

Skip To Voice Support Menu
For Body
For Menu
For Local Menu

Home > News > 2009

December

Dec 18

Prophylaxis of Influenza in Infants and Children Approved as an Additional Indication of Anti-influenza Drug Tamiflu^®

[

PDF 186KB]

Dec 15

Regarding the Incidence of Insider Trading on Chugai Stock

[

PDF 17KB]

Dec 10

Organizational Restructuring and Personnel Changes

[

PDF 78KB]

Dec 04

Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSTEM^®

[

PDF 35KB]

November

Nov 28

Regarding Today's Media Reporting

[

PDF 17KB]

Nov 25

Chugai Revises Corporate Advertisement for First Time in Four Years

[

PDF 243KB]

Nov 20

ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)

[

PDF 96KB]

Nov 19

Recombinant Human Erythropoietin, Epogin^® Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia

[

PDF 168KB]

Nov 12

Chugai Presents an Anti-Cancer Charity Concert, "Christmas Concert in Yokohama Featuring Star Philharmonic Chorus"

[

PDF 652KB]

Nov 11

Chugai Presents
"Volunteer for Life: Jose Carreras Christmas Concert" as the Special Co-Sponsor

[

PDF 167KB]

Nov 09

Anti-Malignancy Agent Avastin^®
Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer

[

PDF 72KB]

Nov 06

Notice Concerning the Passing Away of a Chugai Pharmaceutical Director

[

PDF 167KB]

October

Oct 22

New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative

[

PDF 41KB]

Oct 19

ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone

[

PDF 64KB]

Oct 16

Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin^®
Application for Approval of Additional Indication of Breast Cancer

[

PDF 47KB]

Oct 15

F. Hoffmann-La Roche Announces Third Quarter Sales 2009

[

PDF 21KB]

Oct 07

Revision of Financial Outlook for Fiscal Year 2009
(January 1 - December 31, 2009)

[

PDF 42KB]

Oct 05

Contribution of Para-transit Vehicles to Welfare Services

[

PDF 98KB]

Oct 01

Establishment of the Chugai Academy for Advanced Oncology (CHAAO)
- Elevating Japan's cancer treatment to a global level -

[

PDF 48KB]

September

Sep 30

RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis

[

PDF 54KB]

Sep 24

Anti-Cancer Agent Xeloda^® and Avastin^®
Obtained Approval for Additional Indication of Colorectal Cancer

[

PDF 57KB]

Sep 18

Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva^®
Application for Approval of Additional Indication of Pancreatic Cancer

[

PDF 48KB]

Sep 18

Chugai Displays, "Giant Colon", A Giant Size Balloon Art at "Relay for Life 2009"

[

PDF 89KB]

Sep 15

Organizational Restructuring and Personnel Changes

[

PDF 126KB]

Sep 07

Supply Plan of "Tamiflu^®" Anti-influenza Drug

[

PDF 66KB]

August

Aug 31

Reconstruction Support for Devastating Typhoon Disaster Area in the Republic of China

[

PDF 167KB]

Aug 19

Organizational Restructuring and Personnel Changes

[

PDF 80KB]

July

Jul 31

Update on FDA Registration of Actemra^®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis

[

PDF 23KB]

Jul 23

F. Hoffmann-La Roche Announces 2009 Half Year Results

[

PDF 65KB]

Jul 22

Chugai Files NDA for a Renal Anemia Agent R744

[

PDF 15KB]

June

Jun 30

Primary Endpoint Achieved in Phase III Clinical Trial of Epogin^® in Chemotherapy Induced Anemia

[

PDF 18KB]

Jun 11

New Developments for "CHUGAI ONCOLOGY": Establishment of "Cancer Information Guide," a Website for Patients

[

PDF 851KB]

May

May 11

Determination of Terms and Conditions of Stock Options as Stock-based Compensation (Stock Acquisition Rights)

[

PDF 11KB]

April

Apr 24

Chugai to Absorb Wholly-Owned Subsidiary

[

PDF 37KB]

Apr 24

Issuance of Stock Options as Stock-based Compensation(Stock Acquisition Rights)

[

PDF 70KB]

Apr 22

Approval of Partial Change of API Manufacturing Method and Pharmaceutical Formulation of the Recombinant Human Erythropoietin "Epogin^® Injection"

[

PDF 47KB]

Apr 16

F. Hoffmann-La Roche Announces First Quarter Sales 2009

[

PDF 12KB]

Apr 09

Determination of Terms and Conditions of Common Stock Options (Stock Acquisition Rights)

[

PDF 32KB]

March

Mar 25

Notice of Issuance of Common Stock Options (Stock Acquisition Rights)

[

PDF 47KB]

Mar 25

Relationship with the Parent Companies and Related Parties

[

PDF 123KB]

February

Feb 18

License Agreement with Romark Laboratories and Development of Nitazoxanide in Japan

[

PDF 126KB]

Feb 04

Notification Concerning Dividend Distribution

[

PDF 38KB]

Feb 04

Appointments of a New Director and an Auditor

[

PDF 57KB]

Feb 04

Abolishment of Directors' Retirement Benefits and Granting of Stock Options

[

PDF 33KB]

Feb 04

F. Hoffmann-La Roche Announces Financial Results for Fiscal 2008

[

PDF 64KB]

January

Jan 23

Loss of personal information as a result of having a sales vehicle stolen

[

PDF 67KB]

Jan 21

RoACTEMRA^®,a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,Approved in EU for Rheumatoid Arthritis

[

PDF 60KB]

Categories

: Chugai management, including systems, policies and affiliations with other companies as well as financial information
: Environmental measures, social welfare and contributions
: Prescription pharmaceuticals which are listed in the official table of drug prices
: Over-the-counter products information up until 2004
: Compounds in development up until the approval stage and technology alliances
: Manufacturing facilities, production technologies and product supply plans